Skip to main navigation Skip to search Skip to main content

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

  • Ghassan K. Abou-Alfa
  • , Teresa Macarulla
  • , Milind M. Javle
  • , Robin K. Kelley
  • , Sam J. Lubner
  • , Jorge Adeva
  • , James M. Cleary
  • , Daniel V. Catenacci
  • , Mitesh J. Borad
  • , John Bridgewater
  • , William P. Harris
  • , Adrian G. Murphy
  • , Do Youn Oh
  • , Jonathan Whisenant
  • , Maeve A. Lowery
  • , Lipika Goyal
  • , Rachna T. Shroff
  • , Anthony B. El-Khoueiry
  • , Bin Fan
  • , Bin Wu
    • Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu

Research output: Contribution to journal › Article › peer-review

946   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Keyphrases